These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 31212653)

  • 41. Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer.
    Cheng Y; Wang T; Lv X; Li R; Yuan L; Shen J; Li Y; Yan T; Liu B; Wang L
    Cancer Manag Res; 2020; 12():2069-2078. PubMed ID: 32256114
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.
    Koh Y; Yagi S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Higuchi M; Kanbara H; Nakanishi M; Ueda H; Yamamoto N
    Clin Lung Cancer; 2019 Jul; 20(4):270-277.e1. PubMed ID: 31005568
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gene expression profiling of circulating tumor cells captured by MicroCavity Array is superior to enumeration in demonstrating therapy response in patients with newly diagnosed advanced and locally advanced non-small cell lung cancer.
    Cohen EN; Jayachandran G; Gao H; Peabody P; McBride HB; Alvarez FD; Bravo PL; Qiao W; Liu S; Yao L; Lin SH; Reuben JM
    Transl Lung Cancer Res; 2023 Jan; 12(1):109-126. PubMed ID: 36762061
    [TBL] [Abstract][Full Text] [Related]  

  • 45. EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy.
    Chebouti I; Kasimir-Bauer S; Buderath P; Wimberger P; Hauch S; Kimmig R; Kuhlmann JD
    Oncotarget; 2017 Jul; 8(30):48820-48831. PubMed ID: 28415744
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of circulating tumor cells and evaluation of epithelial-mesenchymal transition patterns of circulating tumor cells in ovarian cancer.
    Jie XX; Zhang M; Du M; Cai QQ; Cong Q; Xu CJ; Zhang XY
    Transl Cancer Res; 2022 Aug; 11(8):2636-2646. PubMed ID: 36093536
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from Prostate Cancer Patients.
    Roumeliotou A; Strati A; Chamchougia F; Xagara A; Tserpeli V; Smilkou S; Lagopodi E; Christopoulou A; Kontopodis E; Drositis I; Androulakis N; Georgoulias V; Koinis F; Kotsakis A; Lianidou E; Kallergi G
    Cells; 2024 May; 13(9):. PubMed ID: 38727318
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enumeration and molecular characterization of circulating tumor cells enriched by microcavity array from stage III non-small cell lung cancer patients.
    Cohen EN; Jayachandran G; Gao H; Qiao W; Liu S; He J; Qiao Y; Yao L; Lin SH; Reuben JM
    Transl Lung Cancer Res; 2020 Oct; 9(5):1974-1985. PubMed ID: 33209617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatocellular Carcinoma-Circulating Tumor Cells Expressing PD-L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors.
    Winograd P; Hou S; Court CM; Lee YT; Chen PJ; Zhu Y; Sadeghi S; Finn RS; Teng PC; Wang JJ; Zhang Z; Liu H; Busuttil RW; Tomlinson JS; Tseng HR; Agopian VG
    Hepatol Commun; 2020 Oct; 4(10):1527-1540. PubMed ID: 33024921
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diversity of Epithelial-Mesenchymal Phenotypes in Circulating Tumour Cells from Prostate Cancer Patient-Derived Xenograft Models.
    Hassan S; Blick T; Thompson EW; Williams ED
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34206049
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A preliminary study on the association between epithelial-mesenchymal transition and circulating tumor cells in renal cell carcinoma.
    Wang H; Li H; Yuan Y; Hao T; Zou B; Yu B; Li S; Zhang J
    Transl Androl Urol; 2022 Apr; 11(4):460-471. PubMed ID: 35558268
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
    Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
    BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study.
    Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Togo S; Shimizu H; Saito M
    J Transl Med; 2018 Oct; 16(1):287. PubMed ID: 30342534
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epithelial-mesenchymal transition classification of circulating tumor cells in lung and colon cancer patients: potential role in clinical practice.
    Fang J; Wang W; Fang J; Wang H; Lin L; Li F; Sun Q; Li F; Qi J; Sun X; Huo XX; Wang S; Wang H; Hong B; Deng Q; Nie J
    Transl Cancer Res; 2020 Nov; 9(11):6639-6651. PubMed ID: 35117274
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer.
    Aghajani MJ; Yang T; Schmitz U; James A; McCafferty CE; de Souza P; Niles N; Roberts TL
    Endocr Connect; 2020 Oct; 9(10):1028-1041. PubMed ID: 33112841
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.
    Polioudaki H; Agelaki S; Chiotaki R; Politaki E; Mavroudis D; Matikas A; Georgoulias V; Theodoropoulos PA
    BMC Cancer; 2015 May; 15():399. PubMed ID: 25962645
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease.
    Mahmood MQ; Ward C; Muller HK; Sohal SS; Walters EH
    Med Oncol; 2017 Mar; 34(3):45. PubMed ID: 28197929
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Establishment and characterization of a patient-derived circulating lung tumor cell line in vitro and in vivo.
    Que Z; Luo B; Zhou Z; Dong C; Jiang Y; Wang L; Shi Q; Tian J
    Cancer Cell Int; 2019; 19():21. PubMed ID: 30718976
    [TBL] [Abstract][Full Text] [Related]  

  • 60. P-Akt/miR‑200 signaling regulates epithelial-mesenchymal transition, migration and invasion in circulating gastric tumor cells.
    Yuan D; Xia H; Zhang Y; Chen L; Leng W; Chen T; Chen Q; Tang Q; Mo X; Liu M; Bi F
    Int J Oncol; 2014 Dec; 45(6):2430-8. PubMed ID: 25200917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.